Maria Carolina Jurcau

Dr. Maria Carolina Jurcau

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CFCIOARA FELICIA
CIOARA FELICIA
AAAdriana Ioana Ardelean
Adriana Ioana Ardelean
Carmen Delia Nistor CseppentoCarmen Delia Nistor Cseppento
Carmen Delia Nistor Cseppento
AJAnamaria Jurcau
Anamaria Jurcau
MJMaria Carolina Jurcau
Maria Carolina Jurcau
FMFlorin Florin Marcu
Florin Florin Marcu
Aging is the most prominent risk factor for late-onset Alzheimer’s disease. Aging associates with a chronic inflammatory state both in the periphery and in the central nervous system, the evidence thereof and the mechanisms leading to chronic neuroinflammation being discussed. Nonetheless, neuroinflammation is significantly enhanced by the accumulation of amyloid beta and accelerates the progression of Alzheimer’s disease through various pathways discussed in the present review. Decades of clinical trials targeting the 2 abnormal proteins in Alzheimer’s disease, amyloid beta and tau, led to many failures. As such, targeting neuroinflammation via different strategies could prove a valuable therapeutic strategy, although much research is still needed to identify the appropriate time window. Active research focusing on identifying early biomarkers could help translating these novel strategies from bench to bedside.

20 November 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
Carmen Delia Nistor CseppentoCarmen Delia Nistor Cseppento
Carmen Delia Nistor Cseppento
MJMaria Carolina Jurcau
Maria Carolina Jurcau
MJMaria Carolina Jurcau
Maria Carolina Jurcau
CFCIOARA FELICIA
CIOARA FELICIA
FMFlorin Florin Marcu
Florin Florin Marcu
Stroke is the second cause of disability worldwide as it is expected to increase its incidence and prevalence. Despite efforts to increase the number of patients eligible for recanalization therapies, a significant proportion of stroke survivors remain permanently disabled. This outcome boosted the search for efficient neurorestorative methods. Stem cells act through multiple pathways: cell replacement, the secretion of growth factors, promoting endogenous reparative pathways, angiogenesis, and the modulation of neuroinflammation. Although neural stem cells are difficult to obtain, pose a series of ethical issues, and require intracerebral delivery, mesenchymal stem cells are less immunogenic, are easy to obtain, and can be transplanted via intravenous, intra-arterial, or intranasal routes. Extracellular vesicles and exosomes have similar actions and are easier to obtain, also allowing for engineering to deliver specific molecules or RNAs and to promote the desired effects. Appropriate timing, dosing, and delivery protocols must be established, and the possibility of tumorigenesis must be settled. Nonetheless, stem cell- and cell-based therapies for stroke have already entered clinical trials. Although safe, the evidence for efficacy is less impressive so far. Hopefully, the STEP guidelines and the SPAN program will improve the success rate. As such, stem cell- and cell-based therapy for ischemic stroke holds great promise.

2 December 2024 in Stresses
Verified
Journal Article
Open access
PDF file
MJMaria Carolina Jurcau
Maria Carolina Jurcau
AJAnamaria Jurcau
Anamaria Jurcau
RDRazvan-Gabriel Diaconu
Razvan-Gabriel Diaconu
Neurodegenerative diseases are devastating conditions with a rising incidence and prevalence due to the aging of the population for which we currently do not have efficient therapies. Despite compelling evidence provided by basic research on the involvement of oxidative stress in their pathogenesis, most trials with antioxidants have failed. The reasons may relate to the low bioavailability of the used compounds or to starting therapy late, when the pathogenic cascades have already induced irreversible damage. The current review discusses the sources of oxidative stress in the central nervous system, the involvement of reactive oxygen species in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, and the importance of further research on improved delivery methods of antioxidants as well as the search for biomarkers that could help in early diagnosis in the hope of finding more efficient therapies for these diseases.

7 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
VNVHAROON SHARMA NUNKOO
VHAROON SHARMA NUNKOO
ACAlexander Cristian
Alexander Cristian
AJAnamaria Jurcau
Anamaria Jurcau
RDRazvan Gabriel Diaconu
Razvan Gabriel Diaconu
MJMaria Carolina Jurcau
Maria Carolina Jurcau
The impressive achievements made in the last century in extending the lifespan have led to a significant growth rate of elderly individuals in populations across the world and an exponential increase in the incidence of age-related conditions such as cardiovascular diseases, diabetes mellitus type 2, and neurodegenerative diseases. To date, geroscientists have identified 12 hallmarks of aging (genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, impaired macroautophagy, mitochondrial dysfunction, impaired nutrient sensing, cellular senescence, stem cell exhaustion, defective intercellular communication, chronic inflammation, and gut dysbiosis), intricately linked among each other, which can be targeted with senolytic or senomorphic drugs, as well as with more aggressive approaches such as cell-based therapies. To date, side effects seriously limit the use of these drugs. However, since rejuvenation is a dream of mankind, future research is expected to improve the tolerability of the available drugs and highlight novel strategies. In the meantime, the medical community, healthcare providers, and society should decide when to start these treatments and how to tailor them individually.

7 February 2024 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
AJAnamaria Jurcau
Anamaria Jurcau
ASAurel Simion
Aurel Simion
MJMaria Carolina Jurcau
Maria Carolina Jurcau
Being an inherited neurodegenerative disease with an identifiable genetic defect, Huntington's disease (HD) is a suitable candidate for early intervention, possibly even in the pre-symptomatic stage. Our recent advances in elucidating the pathogenesis of HD have revealed a series of novel potential therapeutic targets, among which immunotherapies are actively pursued in preclinical experiments. This review focuses on the potential of antibody-based treatments targeting various epitopes (of mutant huntingtin as well as phosphorylated tau) that are currently evaluated in vitro and in animal experiments. The references used in this review were retrieved from the PubMed database, searching for immunotherapies in HD, and clinical trial registries were reviewed for molecules already evaluated in clinical trials. Antibody-based therapies have raised considerable interest in a series of neurodegenerative diseases characterized by deposition of aggregated of aberrantly folded proteins, HD included. Intrabodies and nanobodies can interact with mutant huntingtin inside the nervous cells. However, the conflicting results obtained with some of these intrabodies highlight the need for proper choice of epitopes and for developing animal models more closely mimicking human disease. Approval of these strategies will require a considerable financial and logistic effort on behalf of healthcare systems.

30 November 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
CFCIOARA FELICIA
CIOARA FELICIA
AJAnamaria Jurcau
Anamaria Jurcau
MJMaria Carolina Jurcau
Maria Carolina Jurcau
Carmen Delia Nistor CseppentoCarmen Delia Nistor Cseppento
Carmen Delia Nistor Cseppento
ASAurel Simion
Aurel Simion
Statin therapy has been extensively evaluated and shown to reduce the incidence of new or recurrent vascular events, ischemic stroke included. As a consequence, each published guideline pushes for lower low-density cholesterol levels in the population at large, recommending increased statin doses and/or adding new cholesterol-lowering molecules. Neurologists find it sometimes difficult to apply these guidelines, having to confront situations such as (1) ischemic strokes, mainly cardioembolic ones, in patients with already low LDL-cholesterol levels; (2) myasthenic patients, whose lifespan has been extended by available treatment, and whose age and cholesterol levels put them at risk for ischemic stroke; (3) patients with myotonic dystrophy, whose disease often associates diabetes mellitus and heart conduction defects, and in whom blood cholesterol management is also not settled. As such, further trials are needed to address these issues.